Abbott (NYSE:ABT) today announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD). Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott’s HeartMate 3™ heart pumps to their patients.
Apple Said To Be Zeroing In On This Word For AR/VR Products
Apple, Inc. (NASDAQ: AAPL) has long been rumored to be working on its Augmented Reality/Virtual Reality headset.
